Phase II Study of Durvalumab in Combination With Lenalidomide in Relapsed/Refractory NK-T-cell Lymphoma
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Forventet)
Tilmelding
Fase
Fase
- Fase 2
Kontakter og lokationer
Studiesteder
-
-
-
Singapore, Singapore, 119228
- National University Hospital Singapore
-
Singapore, Singapore, 169608
- Singapore General Hospital
-
Singapore, Singapore, 169610
- National Cancer Centre Singapore
-
Singapore, Singapore, 188770
- Raffles Hospital Singapore
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Histologically proven NK/T-cell lymphoma that has relapsed after at least one cycle of induction chemotherapy.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
- Previously treated with at least one cycle of chemotherapy that includes L-asparaginase or gemcitabine.
- Must be aged ≥ 21 years and able to sign informed consent form.
Adequate hematological function (unless abnormalities are related to lymphoma infiltration of the bone marrow or hemophagocytic syndrome related to NKL) within 30 days prior to signing informed consent, including:
- Absolute neutrophil count (ANC) ≥ 1.0 x 109/L
- Platelet count ≥ 50 x 109/L
- Hemoglobin ≥ 8 g/dL
- Must be able to adhere to study visit schedules and other protocol requirements.
Females of childbearing potential must:
- Have 2 negative pregnancy tests as verified by a Study Investigator prior to starting study therapy. She must agree to ongoing pregnancy testing during the course of the study, and after end of study therapy. This applies even if the patient practices complete abstinence from heterosexual contact.
- Either commit to complete abstinence from heterosexual contact or agree to use, and be able to comply with, effective contraception without interruption, 28 days prior to starting study drug, during the study therapy (including dose interruptions), and for 28 days after discontinuation of study therapy.
- Male patients must practice complete abstinence or agree to use a condom during sexual contact with a pregnant female or female of childbearing potential while participating in the study, during dose interruptions and for 28 days after discontinuation of study therapy, even if he has undergone successful vasectomy.
All patients must:
- Have an understanding that the study drug could have a potential teratogenic risk.
- Agree to abstain from donating blood while taking study drug, during dose interruptions and for 28 days after discontinuation of study therapy.
- Agree not to share study medication with another person.
- Agree to be counseled about pregnancy precautions and risk of fetal exposure.
- Females must agree to abstain from breast feeding during the study participation and for 28 days after discontinuation of study therapy.
- Male subjects should not donate sperm or semen while taking lenalidomide, during breaks (dose interruptions), and for at least 28 days after the last dose of lenalidomide.
Exclusion Criteria:
- Concomitant use of any other investigational agent.
- Known infection with human immunodeficiency virus (HIV).
- Patient has known clinically active hepatitis B; carriers of hepatitis B are permitted but need to be on appropriate anti-viral therapy or have regular hepatitis B DNA virus monitored as advised by a Gastroenterologist.
- Subject has a calculated or measured creatinine clearance of < 30 mL/minute.
- Neuropathy > Grade 2.
- Presence of CNS involvement by lymphoma.
- Myocardial infarction within 6 months prior to enrolment or has New York Hospital Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. Prior to study entry, any ECG abnormality at screening has to be documented by the investigator as not medically relevant.
- Clinically significant active infection or uncontrolled intercurrent illness.
- Pregnant or lactating females.
- Coexistent second malignancy or history of prior malignancy within the preceding 3 years (excluding non-melanoma skin tumors or in situ carcinoma of the cervix).
- Any significant medical or psychiatric condition that might prevent the patient from complying with all study procedures.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Durvalumab and lenalidomide
Open-label use of 2 drugs:
|
Durvalumab intravenous 1500 mg
Lenalidomide oral 20 mg/day
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Effektivitet målt ved den samlede responsrate målt på tidspunktet for bedste respons.
Tidsramme: 2 år
|
Samlet responsrate (ORR) er defineret som andelen af patienter med en reduktion i tumorbyrde på mindst 50 %.
|
2 år
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Progressionsfri overlevelse (PFS)
Tidsramme: 2 år
|
PFS er defineret som tiden fra indskrivning til progression eller død på grund af en hvilken som helst årsag.
Fordelingen af PFS vil blive estimeret ved hjælp af metoden fra Kaplan-Meier.
|
2 år
|
|
Samlet overlevelse (OS)
Tidsramme: 2 år
|
OS er defineret som tiden fra registrering til død på grund af enhver årsag.
Fordelingen af overlevelsestid vil blive estimeret ved hjælp af metoden fra Kaplan-Meier.
|
2 år
|
|
Time-to-response (TTR)
Tidsramme: 2 years
|
Defined for all evaluable patients who have achieved an overall response as the date at which the patient's objective status is first noted to be a CR or PR.
|
2 years
|
|
Duration of response (DoR)
Tidsramme: 2 years
|
Defined for all evaluable patients who have achieved an overall response as the date at which the patient's objective status is first noted to be a CR or PR to the earliest date progression is documented.
|
2 years
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Samarbejdspartnere
Samarbejdspartnere
Datoer for undersøgelser
Studer store datoer
Studiestart (Forventet)
Studiestart
Primær færdiggørelse (Forventet)
Primær færdiggørelse
Studieafslutning (Forventet)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- SDBCC-LYM-16-01
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .